Free Trial

Cara Therapeutics (CARA) Stock Forecast & Price Target

$0.35
-0.01 (-2.76%)
(As of 07/12/2024 ET)

Cara Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

$3.93
1,014.89% Upside
High Forecast$12.00
Average Forecast$3.93
Low Forecast$1.00
TypeCurrent Forecast
7/13/23 to 7/12/24
1 Month Ago
6/13/23 to 6/12/24
3 Months Ago
4/14/23 to 4/13/24
1 Year Ago
7/13/22 to 7/13/23
Consensus Rating
Hold
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
5 Buy rating(s)
Hold
6 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$3.93$11.12$9.75$15.83
Forecasted Upside1,014.89% Upside732.58% Upside496.04% Upside134.37% Upside
Get Cara Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CARA and its competitors with MarketBeat's FREE daily newsletter.

CARA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CARA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Cara Therapeutics Stock vs. The Competition

TypeCara TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.00
2.71
2.50
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside1,014.89% Upside992.53% Upside9.38% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/13/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Hold$10.00 ➝ $1.00+47.17%
6/13/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$6.00 ➝ $1.00+47.17%
6/13/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
O. Livnat
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
6/13/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Stringer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
11/14/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Neutral
5/16/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$6.00 ➝ $4.00-3.61%
3/7/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$19.00 ➝ $16.00+139.16%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 10:15 PM ET.

CARA Forecast - Frequently Asked Questions

What is Cara Therapeutics' forecast for 2024?

According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Cara Therapeutics is $3.93, with a high forecast of $12.00 and a low forecast of $1.00.

Should I buy or sell Cara Therapeutics stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last year. There are currently 6 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CARA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CARA, but not buy additional shares or sell existing shares.

Does Cara Therapeutics's stock price have much upside?

According to analysts, Cara Therapeutics's stock has a predicted upside of 317.73% based on their 12-month stock forecasts.

Has Cara Therapeutics been downgraded by Wall Street analysts recently?

Over the previous 90 days, Cara Therapeutics's stock had 4 downgrades by analysts.

What analysts cover Cara Therapeutics?

Cara Therapeutics has been rated by research analysts at Canaccord Genuity Group, Canaccord Genuity Group, HC Wainwright, Needham & Company LLC, and Stifel Nicolaus in the past 90 days.

Do Wall Street analysts like Cara Therapeutics more than its competitors?

Analysts like Cara Therapeutics less than other "medical" companies. The consensus rating for Cara Therapeutics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CARA compares to other companies.


This page (NASDAQ:CARA) was last updated on 7/12/2024 by MarketBeat.com Staff

From Our Partners